Atlas Trials

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

Clinical trial NCT03410693 · COMPLETED

Trial details

NCT number
NCT03410693
Sponsor
Bayer
Status
COMPLETED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Carcinoma, Transitional Cell
Start date
2018-05-31
Primary completion
2020-10-27
Enrollment
175

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.